Bajaj Healthcare has secured a recommendation from the Subject Expert Committee to manufacture and market the epilepsy drug Cenobamate. This regulatory milestone marks the company's entry into the specialized CNS therapy market. Investors will now balance this future growth potential against the company's recent Q4 FY26 net loss of ₹22.9 crore, as they monitor the path toward commercialization.
What Happened
Bajaj Healthcare has reached a significant regulatory stage after receiving a recommendation from the Subject Expert Committee (SEC) to produce and sell Cenobamate tablets. This drug is used to treat partial-onset seizures in adults. The SEC, which operates under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval for various strengths of the medication, ranging from 12.5 mg to 200 mg. Bajaj Healthcare claims to be the first Indian firm to receive this recommendation for this specific treatment.
Why This Matters For The Business
This move represents a strategic push by Bajaj Healthcare into the specialized Central Nervous System (CNS) therapy market. Cenobamate is a newer treatment option, and the company aims to use this approval to offer a differentiated product in its portfolio. For a pharmaceutical company, securing a regulatory green light is the first major step in commercializing a complex drug. It signals that the company has met specific quality and efficacy standards required by the regulator, which is crucial for competing in the epilepsy treatment space.
Profit, Revenue and Margin Picture
While the regulatory news is positive, investors are also looking at the company's recent financial health. In its fourth-quarter results for the financial year 2026, the company reported a net loss of ₹22.9 crore, compared to a profit of ₹11.2 crore in the same period a year ago. Revenue from operations also dipped slightly by 0.9% to ₹143.6 crore.
However, there is a divergence in the performance metrics. The company's EBITDA, which measures operational profitability, rose by 93% to ₹22.7 crore. The operating margin also improved to 14.8% from 7.6% in the previous year. This indicates that while the core operations are becoming more efficient, the company is facing bottom-line pressure, potentially due to higher interest costs, depreciation, or investments in its pipeline.
How The Stock Reacted
On June 25, 2026, shares of Bajaj Healthcare closed at ₹302.40 on the BSE, down by 2.91%. Investors often react to regulatory news based on the timeline of commercialization. While the approval recommendation is a step forward, the market may be weighing the immediate financial losses against the long-term potential of the new product, especially given that the company has also declared a final dividend of ₹1.50 per share.
What To Watch Next
For investors, the most critical monitorable is the timeline for the final, formal approval from the CDSCO. A recommendation from the SEC is a strong indicator, but the final manufacturing and marketing license is the ultimate trigger for commercial launch. Additionally, the market will monitor how the costs associated with launching this new drug impact the company's cash flow and profit margins in the coming quarters. Investors may also want to track the management's commentary regarding how they plan to fund the expansion and whether the improved operating margins can be sustained during the product launch phase.